HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LF 150195

an immunosuppressive agent

Also Known As:

LF 15-0195; LF-15-0195; LF15-0195

Networked: 9 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amidines: 14
  - Guanidines: 29
    - LF 150195: 9

Experts

1.	Dutartre, P: 4 articles (11/2002 - 05/2001)
2.	Dutartre, Patrick: 3 articles (05/2003 - 08/2002)
3.	Dantal, Jacques: 2 articles (06/2014 - 01/2009)
4.	Le Berre, Ludmilla: 2 articles (06/2014 - 01/2009)
5.	Dubrez-Daloz, Laurence: 2 articles (05/2003 - 01/2003)
6.	Ducoroy, Patrick: 2 articles (05/2003 - 01/2003)
7.	Solary, Eric: 2 articles (05/2003 - 01/2003)
8.	de Fornel, Daniel: 2 articles (05/2003 - 01/2003)
9.	Druet, P: 2 articles (11/2002 - 11/2002)
10.	Duplan, V: 2 articles (11/2002 - 11/2002)

Related Diseases

1.	Autoimmune Diseases (Autoimmune Disease) 08/01/2002 - "These finding suggest that LF 15-0195 is a promising therapeutic for this autoimmune disease."
2.	Vasculitis (Vasculitides) 10/01/2001 - "LF15-0195 is a novel immunosuppressant that is currently in phase II clinical trials for the treatment of vasculitis. " 05/01/2003 - "LF 15-0195 is an immunosuppressive agent obtained by organic synthesis, currently under clinical development for the treatment of vasculitis. "
3.	Glomerulonephritis 10/01/2001 - "LF15-0195 prevents the induction and suppresses the progression of rat anti-GBM disease through multiple mechanisms of action, suggesting that this drug may have significant therapeutic potential in human glomerulonephritis. " 10/01/2001 - "This study examined whether LF15-0195 could suppress the induction and progression of rat anti-glomerular basement membrane (anti-GBM) glomerulonephritis. "
4.	Proteinuria 06/01/2014 - "Only LF15-0195 is able to cause regression of the Buff/Mna nephropathy and to induce regulatory T cells, which decrease proteinuria when transferred into proteinuric Buff/Mna rats. " 01/01/2009 - "Moreover, the transfer of purified LF15-0195-induced CD4+CD25+ T cells to irradiated Buff/Mna rats significantly reduced their proteinuria compared with the transfer of untreated control cells, suggesting that LF15-0195 induces regulatory T cells that are able to induce regression of rat nephropathy. " 10/01/2001 - "Continuous LF15-0195 treatment during the induction of anti-GBM disease (experiment 1) prevented proteinuria and loss of renal function, and markedly reduced histological kidney lesions and renal fibrosis. " 01/01/2009 - "Although corticosteroids, cyclosporin A, and anti-T cell receptor treatment reduced proteinuria, only the deoxyspergualin derivative LF15-0195 led to a rapid and complete normalization of proteinuria. "
5.	Experimental Autoimmune Myasthenia Gravis (Autoimmune Experimental Myasthenia Gravis) 08/01/2002 - "LF 15-0195 prevents from the development and inhibits the progression of rat experimental autoimmune myasthenia gravis." 11/01/2002 - "The immunosuppressant LF 15-0195 prevents experimental autoimmune myasthenia gravis in Brown-Norway rats."

Related Drugs and Biologics

1.	Immunosuppressive Agents (Immunosuppressants)
2.	antiglomerular basement membrane antibody
3.	gusperimus
4.	Interleukin-10 (Interleukin 10)
5.	Cyclosporine (Ciclosporin)
6.	Cytokines
7.	Adrenal Cortex Hormones (Corticosteroids)
8.	Thomsen-Friedenreich antibodies

Related Therapies and Procedures

1.	Therapeutics
2.	Subcutaneous Injections